Page last updated: 2024-11-07

glycylphenylalanine 2-naphthylamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

glycylphenylalanine 2-naphthylamide: cathepsin C substrate; RN given refers to (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

glycyl-L-phenylalanine 2-naphthylamide : An N-(2-naphthyl)carboxamide obtained by formal condensation of the carboxy group of glycyl-L-phenylalanine with the amino group of 2-naphthylamine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID152423
CHEMBL ID22827
CHEBI ID90734
SCHEMBL ID3103486
MeSH IDM0123949

Synonyms (25)

Synonym
gly-phe beta-naphthylamide, crystalline
glycylphenylalanine 2-naphthylamide
CHEMBL22827
chebi:90734 ,
(2s)-2-[(2-aminoacetyl)amino]-n-naphthalen-2-yl-3-phenylpropanamide
glycyl-l-phenylalanine 2-naphthylamide
21438-66-4
glycyl-l-phenylalanine-beta-naphthylamide
l-phenylalaninamide, glycyl-n-2-naphthalenyl-
gly-phe-naphthylamide
SCHEMBL3103486
gly-phe 2-naphthylamide
gly-l-phe 2-naphthylamide
l-phenylalaninamide,glycyl-n-2-naphthalenyl-
mfcd00021597
J-014070
Q27162699
(s)-2-(2-aminoacetamido)-n-(naphthalen-2-yl)-3-phenylpropanamide
h-gly-phe-beta-na
DTXSID50944021
2-[(2-amino-1-hydroxyethylidene)amino]-n-(naphthalen-2-yl)-3-phenylpropanimidic acid
glycylphenylalanine2-naphthylamide
glycyl-n-2-naphthalenyl-l-phenylalaninamide
gly-phe beta -naphthylamide
HY-W011063
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
chromogenic compoundColourless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into coloured compounds. They are used in biochemical assays and in diagnosis as indicators, particularly in the form of enzyme substrates.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
N-(2-naphthyl)carboxamideAny carboxamide resulting from the formal condensation of a carboxylic acid with 2-naphthylamine.
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID197595Lysozyme-conjugated prodrugs: in vitro stability at pH 51992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID197599Lysozyme-conjugated prodrugs: in vitro stability at pH 51992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID197603Lysozyme-conjugated prodrugs: in vitro stability at pH 51992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID197727Lysozyme-conjugated prodrugs: in vitro stability at pH 7.41992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID197597Lysozyme-conjugated prodrugs: in vitro stability at pH 7.41992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
AID197601Lysozyme-conjugated prodrugs: in vitro stability at pH 7.41992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (28.57)18.7374
1990's7 (25.00)18.2507
2000's5 (17.86)29.6817
2010's6 (21.43)24.3611
2020's2 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.15 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (96.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]